Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Sep;116(1):1668–1672. doi: 10.1111/j.1476-5381.1995.tb16389.x

Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model.

T Mori 1, Y Ishigai 1, A Fukuzawa 1, K Chiba 1, T Shibano 1
PMCID: PMC1908907  PMID: 8564235

Abstract

1. The aim of the present study was to determine whether antianginal efficacy of semotiadil fumarate (SD-3211), a structurally novel calcium antagonist, is distinct from those of diltiazem, nifedipine and nisoldipine. 2. First, the duration of the inhibitory effects of semotiadil was compared with that of other Ca2+ antagonists in rat experimental angina evoked by vasopressin. Semotiadil (10 mg kg-1, p.o.) was effective for at least 9 h in the anginal model and those effects of semotiadil were longer-lasting than those of diltiazem (30 mg kg-1, p.o.), nifedipine (10 mg kg-1, p.o.), and nisoldipine (3 mg.kg-1, p.o.). 3. Second, the selectivity of actions of these Ca2+ antagonists for the coronary arteries and myocardium was evaluated in rat isolated perfused hearts. Diltiazem (10(-6) M) reduced cardiac contractility without inhibiting the elevation of perfusion pressure evoked by acetylcholine. Semotiadil (10(-7) M) significantly suppressed cardiac contractility and inhibited the coronary response to acetylcholine. In contrast, nifedipine (3 x 10(-9)-3 x 10(-8) M) and nisoldipine (3 x 10(-10)-10(-8) M) did not reduce cardiac contractility at concentrations which significantly inhibited the increase in perfusion pressure to acetylcholine. 4. The selectivity of semotiadil for coronary artery and myocardium is intermediate between diltiazem and dihydropyridines tested in the present study. 5. These findings suggest that semotiadil has an advantage of diltiazem, nifedipine, and nisoldipine in the treatment of angina with regard to long-lasting action and selectivity for coronary artery and myocardium.

Full text

PDF
1668

Images in this article

1671Figure 4
on p.1671

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fujita M., Ito S., Ota A., Kato N., Yamamoto K., Kawashima Y., Yamauchi H., Iwao J. Synthesis and Ca2+ antagonistic activity of 2-[2-[(aminoalkyl)oxy]-5-methoxyphenyl]-3,4-dihydro-4-methyl-3-oxo-2H- 1,4-benzothiazines. J Med Chem. 1990 Jul;33(7):1898–1905. doi: 10.1021/jm00169a011. [DOI] [PubMed] [Google Scholar]
  2. Henry P. D. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol. 1980 Dec 1;46(6):1047–1058. doi: 10.1016/0002-9149(80)90366-5. [DOI] [PubMed] [Google Scholar]
  3. Hiramatsu Y., Izumi A., Tezuka T., Kurosawa Y. Antagonizing substances obtained from whale heart extract to vasopressin induced myocardial hypoxia. Jpn J Pharmacol. 1970 Sep;20(3):313–324. doi: 10.1254/jjp.20.313. [DOI] [PubMed] [Google Scholar]
  4. Kageyama M., Nishimura K., Takada T., Miyawaki N., Yamauchi H. SD-3211, a novel benzothiazine calcium antagonist, alone and in combination with a beta-adrenoceptor antagonist, produces antihypertensive effects without affecting heart rate and atrioventricular conduction in conscious renal hypertensive dogs. J Cardiovasc Pharmacol. 1991 Jan;17(1):102–107. doi: 10.1097/00005344-199101000-00015. [DOI] [PubMed] [Google Scholar]
  5. Kanda A., Hashimoto H. Effects of semotiadil fumarate, a novel calcium antagonist, on blood pressure and heart rate in conscious spontaneously hypertensive rats. Jpn J Pharmacol. 1993 Sep;63(1):121–124. doi: 10.1254/jjp.63.121. [DOI] [PubMed] [Google Scholar]
  6. Karasawa A., Kubo K., Shuto K., Oka T., Nakamizo N. Antianginal effects of the new calcium antagonist benidipine hydrochloride in anesthetized rats and spontaneously hypertensive rats. Electrocardiographic study. Arzneimittelforschung. 1988 Nov;38(11A):1702–1707. [PubMed] [Google Scholar]
  7. Kendall H. E., Luscombe D. K. Calcium channel blocking drugs. Prog Med Chem. 1987;24:249–297. doi: 10.1016/s0079-6468(08)70424-7. [DOI] [PubMed] [Google Scholar]
  8. Kita Y., Ozaki R., Sakai S., Sugimoto T., Hirasawa Y., Ohtsuka M., Senoh H., Yoshida K., Maeda K. Antianginal effects of FK409, a new spontaneous NO releaser. Br J Pharmacol. 1994 Dec;113(4):1137–1140. doi: 10.1111/j.1476-5381.1994.tb17115.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kottegoda S. R., Adaikan P. G., Karim S. M. Reversal of vasopressin-induced coronary vasoconstriction by a PGE1 analogue (ONO 1206) in primates. Prostaglandins Leukot Med. 1982 Apr;8(4):343–348. doi: 10.1016/0262-1746(82)90057-9. [DOI] [PubMed] [Google Scholar]
  10. Mitchell J., Frishman W., Heiman M. Nisoldipine: a new dihydropyridine calcium-channel blocker. J Clin Pharmacol. 1993 Jan;33(1):46–52. doi: 10.1002/j.1552-4604.1993.tb03902.x. [DOI] [PubMed] [Google Scholar]
  11. Miyawaki N., Furuta T., Shigei T., Yamauchi H., Iso T. Cardiovascular characterization of SD-3211, a novel benzothiazine calcium channel blocker, in isolated rabbit hearts. Life Sci. 1991;48(20):1903–1909. doi: 10.1016/0024-3205(91)90222-w. [DOI] [PubMed] [Google Scholar]
  12. Miyawaki N., Furuta T., Shigei T., Yamauchi H., Iso T. Electrophysiological properties of SD-3211, a novel putative Ca2+ antagonist, in isolated guinea pig and rabbit hearts. J Cardiovasc Pharmacol. 1990 Nov;16(5):769–775. doi: 10.1097/00005344-199011000-00012. [DOI] [PubMed] [Google Scholar]
  13. Nakayama K., Morimoto K., Nozawa Y., Tanaka Y. Calcium antagonistic and binding properties of semotiadil (SD-3211), a benzothiazine derivative assessed in cerebral and coronary arteries. J Cardiovasc Pharmacol. 1992 Sep;20(3):380–391. doi: 10.1097/00005344-199209000-00007. [DOI] [PubMed] [Google Scholar]
  14. Nakayama K., Nozawa Y., Fukuta Y. Allosteric interaction of semotiadil fumarate, a novel benzothiazine, with 1,4-dihydropyridines, phenylalkylamines, and 1,5-benzothiazepines at the Ca(2+)-channel antagonist binding sites in canine skeletal muscle membranes. J Cardiovasc Pharmacol. 1994 May;23(5):731–740. doi: 10.1097/00005344-199405000-00007. [DOI] [PubMed] [Google Scholar]
  15. Okumura K., Yasue H., Matsuyama K., Goto K., Miyagi H., Ogawa H., Matsuyama K. Sensitivity and specificity of intracoronary injection of acetylcholine for the induction of coronary artery spasm. J Am Coll Cardiol. 1988 Oct;12(4):883–888. doi: 10.1016/0735-1097(88)90449-4. [DOI] [PubMed] [Google Scholar]
  16. Opie L. H. Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials. Cardiovasc Drugs Ther. 1988 Jan;1(5):461–491. doi: 10.1007/BF02125731. [DOI] [PubMed] [Google Scholar]
  17. Quartaroli M., Gambini F., Tarter G., Micheli D., Trist D. G., Gaviraghi G. The hemodynamic effects of lacidipine in anesthetized dogs: comparison with nitrendipine, amlodipine, verapamil, and diltiazem. J Cardiovasc Pharmacol. 1991 Sep;18(3):326–336. doi: 10.1097/00005344-199109000-00004. [DOI] [PubMed] [Google Scholar]
  18. Sakai K. Coronary vasoconstriction by locally administered acetylcholine, carbachol and bethanechol in isolated, donor-perfused, rat hearts. Br J Pharmacol. 1980 Apr;68(4):625–632. doi: 10.1111/j.1476-5381.1980.tb10853.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sakai K. Vasoconstriction produced by intracoronary cholinomimetic drugs in isolated donor-perfused hearts of rhesus monkeys: comparison with pig, dog, and rabbit hearts. J Cardiovasc Pharmacol. 1981 May-Jun;3(3):500–509. doi: 10.1097/00005344-198105000-00009. [DOI] [PubMed] [Google Scholar]
  20. Taira N. Differences in cardiovascular profile among calcium antagonists. Am J Cardiol. 1987 Jan 30;59(3):24B–29B. doi: 10.1016/0002-9149(87)90078-6. [DOI] [PubMed] [Google Scholar]
  21. Takada T., Miyawaki N., Kageyama M., Matsuno K., Ishida N., Yamauchi H., Iso T. Antihypertensive effect of a novel calcium antagonist, SD-3211, in experimental hypertensive rats. J Cardiovasc Pharmacol. 1991 Dec;18(6):855–862. doi: 10.1097/00005344-199112000-00011. [DOI] [PubMed] [Google Scholar]
  22. Takada T., Miyawaki N., Nishimura K., Nakata K., Matsuno K., Ishida N., Yamauchi H., Iso T. Cardiohemodynamic effect of a novel calcium antagonist, SD-3211, in the dog. Arch Int Pharmacodyn Ther. 1991 Jan-Feb;309:75–87. [PubMed] [Google Scholar]
  23. Tsuboi T., Hatano N., Nakatsuji K., Fujitani B., Yoshida K., Shimizu M., Kawasaki A., Sakata M., Tsuboshima M. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther. 1980 Sep;247(1):89–102. [PubMed] [Google Scholar]
  24. Uchida W., Shibasaki K., Asano M., Takenaka T. Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701–708. doi: 10.1097/00005344-199305000-00003. [DOI] [PubMed] [Google Scholar]
  25. Yasue H., Horio Y., Nakamura N., Fujii H., Imoto N., Sonoda R., Kugiyama K., Obata K., Morikami Y., Kimura T. Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation. 1986 Nov;74(5):955–963. doi: 10.1161/01.cir.74.5.955. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES